Feminax Ultra

Quick links

Choose a section

Quick links to important sections

Advertisements

Feminax Ultra

Advertisements
Advertisements

Overview of Feminax Ultra

Property Description
Active ingredient Naproxen Sodium
Form Film-coated tablets
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use General pain relief (Analgesic)
Origin Synthetic (Propionic Acid Derivative)

Feminax Ultra: Classification and Core Identity

Feminax Ultra is a single-ingredient oral analgesic formulated as a fast-acting, systemic medicine. Its active substance is Naproxen Sodium, which identifies the medicine as belonging to the pharmacological class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This classification indicates that the compound works by interfering with the body's inflammatory cascade. The formulation is presented as film-coated tablets, designed for ease of oral administration and consistent systemic delivery.

This particular formulation is positioned for the effective management of discomfort, including that related to menstrual cycles. The inclusion of the sodium salt in its composition is a key feature that is clinically recognized for enhancing the substance’s solubility. This chemical modification expedites absorption, translating to a faster onset of action when compared to generic, unmodified naproxen formulations.

General Purpose and Benefit of Feminax Ultra

Its primary purpose is to offer comprehensive relief by mitigating both the physical sensation of pain and the underlying inflammation that often accompanies it. This capability is rooted in its mechanism of inhibiting the production of prostaglandins, chemical messengers that amplify pain signals and trigger inflammatory responses. Naproxen is recognized as an essential medicine due to its established efficacy as a foundational analgesic and anti-inflammatory agent.

For the user, this translates into the provision of sustained relief from acute discomfort. By targeting both the inflammatory process and the transmission of pain signals simultaneously, the medicine’s role is to reduce general aches and tenderness, thereby supporting improved physical function.

Regulatory References

  1. NIH's DailyMed database
  2. World Health Organization (WHO)
Advertisements

What side effects are possible with Feminax Ultra?

Possible Side Effects and Safety Information

Feminax Ultra (Naproxen) is a nonsteroidal anti-inflammatory drug (NSAID) and is associated with officially documented safety considerations, particularly concerning cardiovascular and gastrointestinal risks.

Serious and Clinically Significant Adverse Reactions

Regulatory authorities have issued a Boxed Warning for naproxen, the active ingredient. This warning highlights two major risks:

  • Cardiovascular Thrombotic Events: NSAIDs increase the risk of serious (and potentially fatal) cardiovascular events, including heart attack and stroke. The risk may increase with duration of use and in patients with pre-existing heart disease. The medicine is strictly contraindicated for pain treatment right before or after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Risk: Naproxen can cause serious gastrointestinal adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These can occur without warning symptoms, and the risk is higher in the elderly.

Common Adverse Reactions

The most commonly reported adverse events often involve the gastrointestinal system and nervous system. These may include dyspepsia (indigestion), abdominal pain, nausea, headache, and dizziness.

Population-Specific and Other Safety Concerns

Safety Consideration Regulatory Note
Pregnancy Avoid use starting at 30 weeks gestation due to the risk of fetal ductus arteriosus closure.
Hypersensitivity Contraindicated in patients with a history of asthma, hives, or allergic reactions after taking aspirin or other NSAIDs (aspirin-sensitive asthma).
Fluid/Renal Use is cautioned in patients with heart failure, high blood pressure, or renal impairment due to the potential for fluid retention, edema, and worsening kidney function.
Skin/Liver Naproxen has been associated with serious, sometimes fatal, skin reactions (e.g., Stevens-Johnson syndrome) and hepatotoxicity (liver injury).

All patients are advised to use the lowest effective dose for the shortest possible duration consistent with treatment goals.

Advertisements

Overdose and Emergency Response

Documented Overdose Manifestations

The officially documented presentations of Naproxen Sodium overdose can range from mild to severe. Initial signs commonly listed in regulatory sources include nausea, vomiting, abdominal pain, stomach pain, drowsiness, disorientation, and ringing in the ears (tinnitus). Severe overdose is associated with documented critical neurological and systemic outcomes, including coma, seizures (convulsions), profound altered mental status, and acute renal failure (kidney failure). Other life-threatening manifestations described in regulatory documentation include anion gap metabolic acidosis and significant digestive tract bleeding.

Mandated Emergency Actions

Immediate medical attention is required upon the suspicion or confirmed ingestion of an overdose. Regulatory guidance explicitly instructs patients to seek medical help right away or to contact a Poison Control Center (1-800-222-1222) or local emergency services. This action is mandated due to the potential for severe, documented complications.

Management and Specific Considerations

No specific antidote is known for Naproxen Sodium overdose. Management procedures detailed in official labeling are focused on supportive measures, which may include the use of activated charcoal and continuous monitoring of vital signs and Electrocardiogram (ECG). Overdose risk for severe consequences is noted to be increased in elderly patients and individuals with underlying hepatic or renal impairment.

Advertisements

Therapeutic Uses of Feminax Ultra

What Feminax Ultra Treats: Main Uses and Benefits

Feminax Ultra provides symptomatic support across several key domains where symptoms relate to inflammatory or irritative states, creating acute discomfort and functional interference. The therapeutic role of its active ingredient, Naproxen Sodium, is consistent with established uses for nonsteroidal anti-inflammatory drugs (NSAIDs) in conditions like primary dysmenorrhoea and other acute pain states.


Relief of Menstrual Cramping and Cyclical Pain

Feminax Ultra is specifically applied during phases of primary dysmenorrhoea when symptoms cluster into patterns of pronounced abdominal cramping and associated lower back pain. This focus offers symptomatic relief that helps patients cope more steadily with difficult, recurrent episodes and supports the maintenance of functional stability during heightened cyclical discomfort. The medicine is commonly used to help with symptoms that create noticeable functional strain, including pain related to headache, toothache, and various musculoskeletal conditions.

Management of Acute Pain and Inflammation

This medication is relevant in contexts involving symptoms of increased discomfort or tension, such as musculoskeletal aches, joint stiffness, and tenderness associated with sprains or flares of inflammatory conditions. It is applied in scenarios where additional management of discomfort is required, providing support that contributes to improved comfort during periods when inflammation is active.


Quick Fact: Relief for Pronounced Pain and Inflammation


Sustained Control of Somatic Symptoms

Feminax Ultra is applicable across domains where short-term symptomatic assistance is appropriate for general acute symptoms. The medicine is relevant for easing symptom fluctuations and is applied in scenarios where additional management of discomfort is required, providing support that helps ease the overall symptom burden.

Advertisements

Eligibility and Restrictions for Use

Feminax Ultra (Naproxen Sodium) eligibility is determined by specific regulatory criteria concerning age, existing medical conditions, and physiological status.

Contraindicated Populations

Official labeling mandates that the medicine must not be used by patients with a known hypersensitivity to naproxen or any other Non-Steroidal Anti-Inflammatory Drug (NSAID), including those with aspirin-sensitive asthma. It is also contraindicated for patients with severe heart failure, active gastrointestinal ulceration or bleeding, and for pain treatment in the setting of Coronary Artery Bypass Graft (CABG) surgery.


Age-Related Eligibility

Age Group Regulatory Status
Adults and Adolescents Use is allowed for individuals 12 years of age and older (non-prescription use).
Children under 12 Use is not recommended; consumers are instructed to ask a doctor.
Older Adults (Age 60+) Requires special consideration due to increased risk of gastrointestinal adverse events.

Conditional Use and Restrictions

Use is not recommended for pregnant individuals starting at 30 weeks gestation and later. Restricted use applies between 20 and 30 weeks gestation. Furthermore, the medicine is not recommended for patients with advanced renal disease or severe hepatic impairment. Caution is advised for those with a history of stomach problems, high blood pressure, or for patients taking anticoagulants.

Advertisements

What should I know about interactions with other medicines?

Feminax Ultra, which contains Naproxen Sodium, has formally documented interaction patterns primarily concerning additive risks and the alteration of co-administered medicine concentrations. Regulatory authorities advise strongly against co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or ketorolac, and analgesic doses of aspirin due to the combined potential for serious gastrointestinal adverse events.

Documented Interaction Outcomes

Official regulatory statements address several key drug classes:

  • Additive Bleeding Risk: Co-administration with anticoagulants (e.g., Warfarin), antiplatelet agents, SSRIs, and corticosteroids is associated with a heightened risk of bleeding and ulceration.
  • Reduced Efficacy: Naproxen may diminish the blood pressure-lowering effects of ACE inhibitors, ARBs, and beta-blockers, and it is documented to reduce the natriuretic (fluid-excreting) effect of diuretics.
  • Altered Exposure: The medicine is documented to increase the blood plasma concentrations of certain products, specifically Digoxin and Lithium, by reducing their normal clearance. Naproxen also reduces the renal clearance of Methotrexate, which may increase its toxicity.
  • Substance Interaction: An increased risk of gastrointestinal bleeding is noted when the product is co-administered with the consumption of three or more alcoholic drinks daily. Specific population-based cautions apply to combining naproxen with ACE inhibitors or ARBs in elderly or renal-impaired patients due to potential functional deterioration.
Advertisements

Mechanism of Action

The action of Feminax Ultra is achieved through the precise pharmacodynamic mechanism of its active ingredient, naproxen sodium, which targets key enzyme systems involved in the regulation of eicosanoid-mediated physiological responses.

Non-Selective Inhibition of the COX Enzyme System

The compound functions primarily as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzyme system, blocking both the COX-1 and COX-2 isoforms. This molecular interaction halts the conversion of arachidonic acid into prostanoids, thereby immediately suppressing the body's primary production pathway for inflammatory mediators.

Modulating Prostaglandin-Driven Physiological Cascades

By significantly reducing the local and systemic concentration of prostaglandins, the drug initiates a cascade of effects that modulates heightened physiological responses. This functions to reduce the effect of elevated mediator activity, notably by reducing the sensitization of peripheral nociceptors and dampening prostaglandin-induced smooth muscle hypercontractility.

Mechanism-Dependent Onset Factor

The inclusion of the sodium salt in the formulation is a mechanistic factor that enhances the compound's solubility. This chemical feature supports a more rapid absorption rate, which supports the attainment of the concentration necessary for effective COX enzyme inhibition.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Feminax Ultra, containing naproxen sodium, is administered via the oral route as a film-coated tablet. The administration framework is structured around acute, short-term use, governed by specific dosing parameters and temporal instructions.

The regimen begins with an initial oral dose of 550 mg naproxen sodium, administered once at the onset of symptoms. This starting dose establishes the protocol, which is followed by a maintenance schedule where 275 mg can be taken every 6 to 8 hours, or 550 mg can be taken every 12 hours. The total quantity administered is strictly limited by maximum limits, with the daily dose not to exceed 1375 mg on the first day, and 1100 mg on subsequent days.

The film-coated tablet must be swallowed whole with water. While administration is centered on symptom onset, it is permitted to occur with food or milk. Procedural guidelines specify that use should be the lowest effective dose for the shortest possible duration, restricting the course to the length of the acute episode. Dosage considerations also apply for specific demographics, noting that a lower starting dose should be considered for older adults and patients with documented renal or hepatic impairment.

Advertisements

Recent Clinical Evidence

The Role of Naproxen in Managing Dysmenorrhea

Feminax Ultra contains naproxen 250 mg, which is classified as a non-steroidal anti-inflammatory drug (NSAID). Research confirms the pharmacological action of naproxen involves the non-selective inhibition of cyclooxygenase (COX) enzymes, which in turn reduces the body's production of prostaglandins. Prostaglandins are recognized mediators of inflammation and pain, including the uterine contractions and related pain associated with primary dysmenorrhea (period pain).

Overview of Clinical Outcomes

Clinical trials and systematic reviews, including evidence from the Cochrane Database, have evaluated the effectiveness of naproxen in managing primary dysmenorrhea. Studies indicate that NSAIDs, as a class, are associated with a greater proportion of women achieving pain relief compared to placebo.

Research specifically comparing naproxen to other common analgesics found that:

  • Naproxen was associated with a lower mean score on patient-reported pain scales over a 12-hour period compared to acetaminophen (paracetamol) in single-dose, double-blind trials among women with moderate to severe primary dysmenorrhea.
  • The use of naproxen has been associated with a reduction in daily life restrictions and a reduced need for rescue analgesics when compared with placebo.

Absorption and Timing of Effect

Naproxen sodium, the active ingredient's salt form often used in formulations, is designed for rapid absorption. Peak plasma concentrations are generally observed within 1 to 4 hours after oral administration, although some formulations may achieve peaks faster. The drug's elimination half-life, which typically ranges from 12 to 17 hours, supports a duration of action that allows for sustained relief between doses.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Feminax Ultra (FAQ)

Q: Why does Feminax Ultra specifically state it is for period pain relief?

The regulatory product license defines its primary purpose and indication. According to official product information, Feminax Ultra is specifically licensed for the relief of period pain (known medically as primary dysmenorrhoea). This positioning reflects the scope of its authorization by the national regulatory agency.

Q: How does the active ingredient in Feminax Ultra compare to ibuprofen or paracetamol?

The active ingredient, naproxen, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which works to reduce pain by targeting and reducing inflammation. This mechanism differs from paracetamol (acetaminophen), which primarily acts on the central nervous system to block pain signals. Official regulatory sources define these different classifications.

Q: Is Feminax Ultra a different type of painkiller than a standard over-the-counter medicine?

Official documents classify Feminax Ultra as a Pharmacy (P) medicine in the UK regulatory framework. This means that while it is not a prescription-only drug, it is not available on general sale and must be purchased from a pharmacy under the supervision of a pharmacist.

Q: Is it typical to experience dizziness or drowsiness after taking Feminax Ultra?

Official regulatory documents for the active ingredient list both dizziness and drowsiness (feeling sleepy) as possible known side effects that may occur when using the medicine. If these effects are experienced, individuals should be aware of the impact on daily activities.

Q: Are there any long-term safety considerations for using Feminax Ultra occasionally?

The official product labeling stresses that this medicine is intended for short-term use. Regulatory guidelines universally emphasize the importance of using the lowest effective dose for the shortest possible duration to help mitigate the potential cardiovascular and gastrointestinal risks associated with the NSAID class of drugs.

Q: Why is the medicine recommended for use only on certain days of the menstrual cycle?

This medicine is classified for acute, short-term use, which aligns with the temporary nature of menstrual discomfort. Official administration guidelines mandate that the treatment course should be restricted to the length of the acute episode to ensure compliance with the principle of using the lowest effective dose for the shortest duration.

Q: Does taking Feminax Ultra with food or milk change how quickly it starts to work?

While official administration guidelines state that taking the product with food or milk is permitted, regulatory labeling also indicates that the presence of food may cause the medicine to take longer to start working. This is a factor related to the speed of absorption in the digestive system.

Q: What does it mean that Feminax Ultra is a 'gastro-resistant tablet'?

The term gastro-resistant means the tablet is covered in a special coating that prevents it from dissolving in the stomach's acid. This coating allows the tablet to pass into the small intestine before releasing the active ingredient, which is a design feature intended to reduce irritation to the lining of the stomach.

Q: Can Feminax Ultra be taken simultaneously with paracetamol or co-codamol?

Official regulatory warnings for both naproxen and paracetamol (acetaminophen) highlight separate safety considerations. While the combination is sometimes evaluated, there is a need for caution due to the risk of gastrointestinal side effects from naproxen and the potential for liver toxicity from paracetamol. Regulatory sources suggest caution when combining analgesics.

Q: Is there a known interaction between Feminax Ultra and oral contraceptives (birth control)?

Official regulatory documents and established interaction databases do not commonly list a direct interaction between naproxen and the effectiveness of oral contraceptives. However, due to the complexity of individual health profiles, official sources recommend consulting a healthcare provider for case-specific guidance on medication combinations.

Q: Is there a maximum age limit for using Feminax Ultra for period pain?

According to the official patient information, the product is specifically licensed as suitable for the relief of period pain in women aged 15 to 50 years. This age range is outlined in the dosage and eligibility section of the regulatory documents for this particular indication.

Q: Is Feminax Ultra described as suitable for women who are pregnant or planning a pregnancy?

Studies indicate that the active ingredient may make it harder to get pregnant, and use is generally not recommended when a person is actively trying to conceive. Furthermore, the official labeling states that the medicine is restricted or contraindicated (must not be used) from 20 weeks gestation onwards.

Q: Can men use Feminax Ultra for pain relief if the active ingredient is naproxen?

The specific branded product, Feminax Ultra, is licensed and indicated solely for the treatment of period pain in women. While the active component, naproxen, is used in other medicines to treat general inflammatory conditions in both men and women, this particular product's regulatory license is restricted to women's use for dysmenorrhoea.

Q: Where can I find the official patient information leaflet (PIL) for Feminax Ultra?

The official product documents, such as the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC), can be found by searching the product name on the national regulatory agency's drug database for the country where the medicine was purchased. These databases host validated, authoritative documents.

Q: Does the medicine contain any ingredients that are common allergens?

Yes, the official regulatory labeling provides a complete list of inactive ingredients (excipients), which can include substances like soya oil/lecithin or specific coloring agents that may be common allergens. Official product information advises that patients with known allergies consult the Patient Information Leaflet (PIL) for the full ingredient list.

Q: What should a user do if they miss a scheduled time for taking the medicine?

Official administration guidelines state that if a dose is forgotten, it should be taken as soon as it is remembered, unless it is nearly time for the next dose. In that case, the missed dose should be skipped entirely. Regulatory sources state that a double dose should not be taken to compensate for a missed one.

Q: Is there a risk of developing a dependency on Feminax Ultra?

The active ingredient, naproxen, belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official classification and medical guidance confirm that it is not considered an addictive medication or a narcotic, and there is no documented risk of physical or psychological dependence.

Q: Are there non-period related conditions where the active ingredient is used for inflammation?

The active ingredient, Naproxen, is officially indicated in other medicinal products for a range of inflammatory and pain conditions beyond dysmenorrhoea. These include, but are not limited to, rheumatoid arthritis, osteoarthritis, acute flares of gout, and soft tissue injuries like tendinitis or bursitis.

Q: Are headaches or confusion listed as possible effects in the official safety information?

Official regulatory safety information lists headache as a common adverse event associated with the active ingredient. While less common, confusion is also listed as a possible adverse reaction, which can sometimes be a sign of a more serious, though rare, neurological or systemic reaction.

Advertisements

How should Feminax Ultra be stored and disposed of?

How to Store and Dispose of Feminax Ultra

Feminax Ultra (Naproxen 250 mg) must be stored under specific conditions to ensure its stability and maintain public safety, as defined by regulatory documents.


Storage Requirements

  • Temperature: Store the tablets below 25 C or the maximum temperature specified on the package label.
  • Protection: The medicine must be protected from light and kept in its original outer carton.
  • Safety: Always store Feminax Ultra out of the sight and reach of children.

Disposal Instructions

  • Method: Unused or expired tablets should be disposed of in accordance with local regulations.
  • Preference: Utilize a drug take-back program at a pharmacy or community site where available.
  • Restriction: Do not flush the tablets down the toilet or place them in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Feminax Ultra found in:

A-Z Index: